FMP

FMP

Enter

SRRK - Scholar Rock Ho...

photo-url-https://images.financialmodelingprep.com/symbol/SRRK.png

Scholar Rock Holding Corporation

SRRK

NASDAQ

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

44.78 USD

2.69 (6.01%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. Jay Thomas Backstrom M.D., M.P.H.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients s...

CIK

0001727196

ISIN

US80706P1030

CUSIP

80706P103

Address

301 Binney Street

Phone

857 259 3860

Country

US

Employee

150

IPO Date

May 25, 2018

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

SRRK Financial Summary

CIK

0001727196

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

80706P103

ISIN

US80706P1030

Country

US

Price

44.78

Beta

0.48

Volume Avg.

2.1M

Market Cap

4.19B

Shares

-

52-Week

6.76-46.185

DCF

0.48

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-18.97

P/B

-

Website

https://scholarrock.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest SRRK News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep